TNFRSF8 and lymphoma: Nevertheless, the data on the second-generation CD30-specific Mabs sparked renewed interest in the clinical use of unconjugated CD30-specific antibodies and resulted in multiple clinical trials treating relapsed and refractory patients with CD30+ lymphomas with CD30-specific Mabs.